Abstract: The present invention relates to small cationic ortho-5,15-di-heteroaryl porphyrin derivatives, in particular porphyrins, chlorins or bacteriochlorin of formula (I) or pharmaceutically acceptable salts thereof. This invention also relates to the use of the above-mentioned cationic ortho-5,10-di-heteroaryl porphyrin derivatives of Formula (I) or a pharmaceutically acceptable salts thereof, in photodynamic inactivation of microorganisms, where the referred derivatives are able to treat the same in the presence of an adequate light. The present invention also describes pharmaceutical compositions comprising one or more of the cationic ortho-5,10-di-heteroaryl porphyrin derivatives, in particular prophyrins, chlorins or bacteriochlorins of Formula (I), or pharmaceutically acceptable salts thereof, for the treatment of bacterial and/or fungi and/or yeasts and/or viral infections, in humans or animals.

Abstract: This invention relates to atroipsomers of reduced tetraphenylporphyrin derivatives with halogen atoms (F, Cl, Br) in the ortho positions of the phenyl groups, particularly halogenated tetraphenylchlorins and halogenated tetraphenylbacteriochlorins, which can be used in photodynamic therapy. According to the formulae of the invention, the ortho-phenyl substituents X1, X2, X3, X4, X5, X6, X7 and X8 may be identical or different and represent halogen atoms or hydrogen atoms, provided that at least all of X2, X4, X6 and X8 are halogens, and the meta-phenyl substituents R1, R2, R3 and R4 are independently chosen from —OH, —OR or —SO2R?, where R? are each independently chosen from —Cl, —OH, -aminoacid, —OR, —NHR, or —NR2, where R are alkyl of 1 to 12 carbon atoms or R2 represents cycloalkyl with 2 to 12 carbon atoms. The atropisomers of this invention have the majority of the substituents R1, R2, R3 and R4 on the same side of the plane defined by the macrocycle.

Abstract: The present invention describes methods for obtaining functionalized polymeric surfaces (MPn-PSm) from polymers or copolymers with appropriate functionalizations (X), which can be a halogen of a leaving group, such as polyvinyl chloride (MP1) and (chloromethyl)polystyrene-Merrifield (MP2), and curcumin photosensitizers (PS1), meso-tetra(aryl)porphyrins, chlorins or bacteriochlorins halogenated and functionalized with nucleophilic groups (PS2), in particular including P2 of the type meso-imidazoyl-porphyrins, chlorins or bacteriochlorins (PS3). The structures of all the photosensitizers in the present application incorporate a functional group (Y), which is a OH, SH or NH2nucleophile. The application also describes the covalent bonding process of the photosensitizers PS1-PS3 to the functional polymeric materials MP1-MP2 by means of a nucleophilic substitution reaction to prepare the MPn-Psm products.

Abstract: The present invention relates to carboxamide halogenated porphyrin derivatives, in particular bacteriochlorin or chlorin, of formula (I) use of the same or a pharmaceutically acceptable salt thereof in photodynamic therapy, where the derivatives are able to detect and exhibit the presence of hyperproliferative disorders and, in the presence of an adequate lighting, to treat the same. The present invention also describes a pharmaceutical composition having the carboxamide halogenated porphyrin derivatives, in particular bacteria-chlorin or chlorin, of Formula (I) or a pharmaceutically acceptable salt thereof, for the treatment of cancer and/or microbial and/or viral infections, in humans or animals.

Abstract: This invention relates to atroipsomers of reduced tetraphenylporphyrin derivatives with halogen atoms (F, Cl, Br) in the ortho positions of the phenyl groups, particularly halogenated tetraphenylchlorins and halogenated tetraphenylbacteriochlorins, which can be used in photodynamic therapy. According to the formulae of the invention, the ortho-phenyl substituents X1, X2, X3, X4, X5, X6, X7 and X8 may be identical or different and represent halogen atoms or hydrogen atoms, provided that at least all of X2, X4, X6 and X8 are halogens, and the meta-phenyl substituents R1, R2, R3 and R4 are independently chosen from —OH, —OR or —SO2R?, where R? are each independently chosen from —Cl, —OH, -aminoacid, —OR, —NHR, or —NR2, where R are alkyl of 1 to 12 carbon atoms or R2 represents cycloalkyl with 2 to 12 carbon atoms. The atropisomers of this invention have the majority of the substituents R1, R2, R3 and R4 on the same side of the plane defined by the macrocycle.

Abstract: The present invention relates to carboxamide halogenated porphyrin derivatives, in particular bacteriochlorin or chlorin, of formula (I) use of the same or a pharmaceutically acceptable salt thereof in photodynamic therapy, where the derivatives are able to detect and exhibit the presence of hyperproliferative disorders and, in the presence of an adequate lighting, to treat the same. The present invention also describes a pharmaceutical composition having the carboxamide halogenated porphyrin derivatives, in particular bacteria-chlorin or chlorin, of Formula (I) or a pharmaceutically acceptable salt thereof, for the treatment of cancer and/or microbial and/or viral infections, in humans or animals.

Abstract: The disclosed subject matter includes methods of preparation, properties, pharmaceutical compositions and methods of therapy of sulfonated chlorins and bacteriochlorins designed for the photodynamic therapy (PDT) of hyperproliferative tissues such as tumors, hyperproliferative blood vessels and other disorders or abnormalies that are responsive to PDT. In particular, the economical large-scale synthesis of stable chlorins and bacteriochlorins is described. Their properties were tailored to meet those of ideal photosensitizers for PDT. In another embodiment, pharmaceutical compositions and methods of therapy for systemic administration are provided. In a further embodiment, pharmaceutical compositions and methods of therapy for topical administration are also provided. Further provided is a method of labeling a target tissue and providing an image of that tissue by fluorescence of magnetic resonance imaging.

Abstract: The invention relates to derivatives of porphyrin, particularly chlorins and/or bacteriochlorins, which can be used in photodynamic therapy. According to the formulas of the invention, X1, X2, X3, X4, X5, X6, X7, X8, which may be identical or different, each represent halogen atoms or hydrogen atoms. R1, R2, R3, R4, which may be identical or different, are each selected from the following groups: —OH, amino acids, —OR and —NHR and/or a chlorine atom, wherein R is an alkyl group having between 1 and 12 carbon atoms. The invention also relates to an anticancer and/or antiviral and/or antimicrobial medicament for human or animal use, which contains one or more compounds as the main active ingredient.

Abstract: The disclosed subject matter includes methods of preparation, properties, pharmaceutical compositions and methods of therapy of sulfonated chlorins and bacterioclorins designed for the photodynamic therapy (PDT) of hyperproliferative tissues such as tumors, hyperproliferative blood vessels and other disorders or abnormalities that are responsive to PDT. In particular, the economical large-scale synthesis of stable chlorins and bacteriochlorins is described. Their properties were tailored to meet those of ideal photosensitizers for PDT. In another embodiment, pharmaceutical compositions and methods of therapy for systemic administration are provided. In a further embodiment, pharmaceutical compositions and methods of therapy for topical administration are also provided. Further provided is a method of labeling a target tissue and providing an image of that tissue by fluorescence of magnetic resonance imaging.

Abstract: The invention relates to derivatives of porphyrin, particularly chlorins and/or bacteriochlorins, which can be used in photodynamic therapy. According to the formulas of the invention, X1, X2, X3, X4, X5, X6, X7, X8, which maybe identical or different, each represent halogen atoms or hydrogen atoms. R1, R2, R3, R4, which may be identical or different, are each selected from the following groups: —OH, amino acids, —OR and —NHR and/or a chlorine atom, wherein R is an alkyl group having between 1 and 12 carbon atoms. The invention also relates to an anticancer and/or antiviral and/or antimicrobial medicament for human or animal use, which contains one or more compounds as the main active ingredient.